Dataset Information


Salivary Transcriptomic and Proteomic Biomarkers for Breast Cancer Detection

ABSTRACT: A sensitive assay to identify biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. In this study, we have conducted a prospective sample collection and retrospective blinded validation (PRoBE design) to evaluate the performance and translational utilities of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. The Affymetrix HG U133 Plus 2.0 Array and 2D-DIGE were used to profile transcriptomes and proteomes in saliva supernatants respectively. Significant variations of salivary transcriptomic and proteomic profiles were observed between breast cancer patients and healthy controls. Eleven transcriptomic biomarker candidates and two proteomic biomarker candidates were selected for a preclinical validation using an independent sample set. Transcriptomic biomarkers were validated by RT-qPCR and proteomic biomarkers were validated by quantitative protein immunoblot. Eight mRNA biomarkers and one protein biomarker have been validated for breast cancer detection, yielding ROC-plot AUC values between 0.665 and 0.959. This report provides proof of concept of salivary biomarkers for the non-invasive detection of breast cancer. The salivary biomarkers’ discriminatory power paves the way for a PRoBE-design definitive validation study. Keywords: Salivary biomarker, Breast cancer, Early detection, Salivary transcriptome, Salivary proteome This study, which was approved by the UCLA and Cedars-Sinai Medical Center Institutional Review Boards (#06-07-043 and #3870, respectively), started sample collection in February 2007. The sample collection followed the PRoBE principle (prospective specimen collection). The saliva bank for breast cancer project at the UCLA Dental Research Institute in collaboration with Cedars Sinai Medical Center has collected 200 saliva samples since 2007 with all subjects recruited from the Saul and Joyce Brandman Breast Cancer Center. Of these, 113 samples, including 41 breast cancer patients and 72 healthy control individuals, were selected for the discovery and validation phase of this study. Inclusion criteria of cancer patients consisted of a confirmed diagnosis of breast cancer. Exclusion criteria of cancer patients included therapy/surgery and/or a diagnosis of other malignancies within 5 years prior to saliva collection. Exclusion criteria of control patients included a diagnosis of any malignancies within 5 years prior to saliva collection. Written informed consents and questionnaire data sheets were obtained from all patients who agreed to serve as saliva donors. Unstimulated saliva samples were consistently collected, stabilized, and preserved as previously described. The sample supernatants were reserved at -80 C prior to assay. This study consisted of a discovery phase, followed by an independent preclinical validation phase. Of the 113 samples, 10 breast cancer samples and 10 healthy control samples were chosen for the discovery phase. All breast cancer cases are invasive ductal carcinoma (IDC), the most common type of breast cancer. Biomarkers identified from the discovery studies were first verified using the discovery sample set. An independent sample set, including 31 breast cancer patients and 62 healthy control subjects, was used for the biomarker validation phase.

ORGANISM(S): Homo sapiens  

SUBMITTER: David Akin   Scott Karlan  David Elashoff  Xinmin Yan  David Chia  Lei Zhang  Ziding Feng  David T Wong  Jenny Gross  Hua Xiao  Beth Karlan  Hui Zhou 

PROVIDER: E-GEOD-20266 | ArrayExpress | 2010-02-21



Dataset's files

Action DRS
E-GEOD-20266.README.txt Txt
E-GEOD-20266.eSet.r Other
E-GEOD-20266.idf.txt Idf Processed Raw
Items per page:
1 - 5 of 6

Similar Datasets

| GSE20266 | GEO
2010-01-01 | S-EPMC3013113 | BioStudies
2008-12-31 | GSE14245 | GEO
2008-12-30 | E-GEOD-14245 | ArrayExpress
2012-01-01 | S-EPMC3277759 | BioStudies
2011-01-01 | S-EPMC3043350 | BioStudies
2020-01-01 | S-EPMC7035572 | BioStudies
2010-01-01 | S-EPMC2831159 | BioStudies
| GSE47811 | GEO
2013-06-12 | E-GEOD-47811 | ArrayExpress